Shun-Ichi Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shun-Ichi Watanabe has a total of 350 co-authors. Here are the top co-authors by number of shared publications:
- Yukihiro Yoshida
Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
95 shared publications - Akiyoshi Hirayama
Institute for Advanced Biosciences, Keio University, Yamagata, Japan
70 shared publications - Atsushi Ochiai
Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan
70 shared publications - Hideaki Mizuno
Chugai Pharmaceutical Co., Ltd., Research Division, Yokohama, Kanagawa, Japan
70 shared publications - Hiromi Sakamoto
Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
70 shared publications - Hironori Fukuda
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
70 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes
Purpose: Nivolumab plus ipilimumab is a standard first-line therapy for unresectable malignant pleural mesothelioma (MPM), yet biomarkers predicting immune checkpoint inhibitor (ICI) efficacy remain undefined. We aimed to identify genomic and tumor immune microenvironmental features associated with ICI response in MPM. Experimental Design: We analyzed two independent MPM cohorts. The discovery cohort included patients at the National Cancer Center Hospital (2012–2022) with frozen tumor tissues available for whole-genome sequencing (WGS) and RNA sequencing. Genomic alterations, transcriptomic profiles, immune cell composition, and T-cell receptor repertoire were analyzed, and key findings were validated in a nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort. Results: The WGS cohort comprised 52 patients. Among ICI-treated patients, overall response rates were 30% in the WGS cohort and 29.4% in the C-CAT cohort. Genomic analyses identified frequent alterations in BAP1 and NF2, across both cohorts. ICI responders showed higher T-cell receptor diversity, increased CD8⁺ T-cell infiltration, and enrichment of M1 macrophages compared with non-responders. MTAP loss was associated with higher CD8⁺ T-cell infiltration and T-cell receptor diversity, and was linked to a higher ICI response rate in the C-CAT cohort. In contrast, BAP1 and NF2 alterations showed no consistent association with immune features or ICI efficacy. Conclusions: An immune-active tumor microenvironment characterized by high T-cell receptor diversity, CD8⁺ T-cell infiltration, and M1 macrophage enrichment was associated with favorable ICI responses in MPM. MTAP loss was linked to immune-related features and a higher ICI response, supporting further investigation of MTAP loss as a candidate biomarker.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes
Purpose: Nivolumab plus ipilimumab is a standard first-line therapy for unresectable malignant pleural mesothelioma (MPM), yet biomarkers predicting immune checkpoint inhibitor (ICI) efficacy remain undefined. We aimed to identify genomic and tumor immune microenvironmental features associated with ICI response in MPM. Experimental Design: We analyzed two independent MPM cohorts. The discovery cohort included patients at the National Cancer Center Hospital (2012–2022) with frozen tumor tissues available for whole-genome sequencing (WGS) and RNA sequencing. Genomic alterations, transcriptomic profiles, immune cell composition, and T-cell receptor repertoire were analyzed, and key findings were validated in a nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort. Results: The WGS cohort comprised 52 patients. Among ICI-treated patients, overall response rates were 30% in the WGS cohort and 29.4% in the C-CAT cohort. Genomic analyses identified frequent alterations in BAP1 and NF2, across both cohorts. ICI responders showed higher T-cell receptor diversity, increased CD8⁺ T-cell infiltration, and enrichment of M1 macrophages compared with non-responders. MTAP loss was associated with higher CD8⁺ T-cell infiltration and T-cell receptor diversity, and was linked to a higher ICI response rate in the C-CAT cohort. In contrast, BAP1 and NF2 alterations showed no consistent association with immune features or ICI efficacy. Conclusions: An immune-active tumor microenvironment characterized by high T-cell receptor diversity, CD8⁺ T-cell infiltration, and M1 macrophage enrichment was associated with favorable ICI responses in MPM. MTAP loss was linked to immune-related features and a higher ICI response, supporting further investigation of MTAP loss as a candidate biomarker.
- 29 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)
The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.
- 29 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)
The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.
- 25 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Preclinical Evaluation of Liposomal Eribulin in a Panel of Sarcoma Patient-Derived Xenograft Models
Sarcomas are rare, heterogeneous tumors with poor prognoses, underscoring the urgent need for novel therapies. Liposomal eribulin (E7389-LF) was developed to improve the efficacy and safety profile of eribulin; however, its preclinical evaluation in sarcomas remains limited. This study aimed to evaluate the clinical applicability of E7389-LF by comprehensively comparing it with eribulin using 12 patient-derived xenograft (PDX) models representing 6 sarcoma subtypes. Antitumor activity was assessed across 5 treatment groups, including independently scaled, clinically relevant regimens of eribulin (0.47 mg/kg) and E7389-LF (0.77 mg/kg). Pharmacokinetic (PK) analyses were performed using liquid chromatography/tandem mass spectrometry and fluorescence immunostaining. In addition, correlations between antitumor activity and clinical efficacy were descriptively investigated. Treatment with E7389-LF (0.77 mg/kg) induced tumor regression in 7 of 12 (58%) models, compared with 4 of 12 (33%) models treated with eribulin (0.47 mg/kg). Notable responses were observed in rhabdomyosarcoma, Ewing sarcoma, and leiomyosarcoma models. No apparent weight loss was observed in either treatment group. PK analyses indicated increased systemic and intratumoral drug exposure with E7389-LF. In 3 PDX models derived from patients treated with eribulin, tumor responses reflected the corresponding clinical outcomes, providing preliminary evidence for the translational relevance of these models. This study demonstrates that E7389-LF exerts antitumor activity broadly comparable with eribulin and exerts antitumor activity in several models across PDX models of sarcoma, with favorable tolerability and improved intratumoral drug retention. These findings support the clinical development of E7389-LF for patients with sarcoma who have limited treatment options.
- 25 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Preclinical Evaluation of Liposomal Eribulin in a Panel of Sarcoma Patient-Derived Xenograft Models
Sarcomas are rare, heterogeneous tumors with poor prognoses, underscoring the urgent need for novel therapies. Liposomal eribulin (E7389-LF) was developed to improve the efficacy and safety profile of eribulin; however, its preclinical evaluation in sarcomas remains limited. This study aimed to evaluate the clinical applicability of E7389-LF by comprehensively comparing it with eribulin using 12 patient-derived xenograft (PDX) models representing 6 sarcoma subtypes. Antitumor activity was assessed across 5 treatment groups, including independently scaled, clinically relevant regimens of eribulin (0.47 mg/kg) and E7389-LF (0.77 mg/kg). Pharmacokinetic (PK) analyses were performed using liquid chromatography/tandem mass spectrometry and fluorescence immunostaining. In addition, correlations between antitumor activity and clinical efficacy were descriptively investigated. Treatment with E7389-LF (0.77 mg/kg) induced tumor regression in 7 of 12 (58%) models, compared with 4 of 12 (33%) models treated with eribulin (0.47 mg/kg). Notable responses were observed in rhabdomyosarcoma, Ewing sarcoma, and leiomyosarcoma models. No apparent weight loss was observed in either treatment group. PK analyses indicated increased systemic and intratumoral drug exposure with E7389-LF. In 3 PDX models derived from patients treated with eribulin, tumor responses reflected the corresponding clinical outcomes, providing preliminary evidence for the translational relevance of these models. This study demonstrates that E7389-LF exerts antitumor activity broadly comparable with eribulin and exerts antitumor activity in several models across PDX models of sarcoma, with favorable tolerability and improved intratumoral drug retention. These findings support the clinical development of E7389-LF for patients with sarcoma who have limited treatment options.
- 17 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109418
Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples
- 17 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109418
Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples
- 26 March 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109386
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung
- 26 March 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109386
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung
- 6 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (1)
Patient-Reported Outcomes in Thoracic Surgery: An International Survey of European Society of Thoracic Surgeons (ESTS) and Japanese Association for Chest Surgery (JACS) Members
Objectives: This study aimed to evaluate the progress in the collection and interpretation of patient-reported outcomes (PRO) and health-related quality of life (HRQoL) in thoracic surgery. Methods: We invited all members of the European Society of Thoracic Surgeons (ESTS) and the Japanese Association for Chest Surgery (JACS) via e-mail, providing survey information in both English and Japanese. It consisted of 19 questions addressing the use of HRQoL assessment in clinical practice. Results: In total, we received 234 responses: 84 from ESTS, 128 from JACS, and 22 from other societies. The present survey showed that 58.5% of surgeons have never collected HRQoL data in their practice. The EORTC-QLQ-LC29 was the most frequently used questionnaire, reported by 24.7% of participants. A total of 137 (59.6%) responses identified HRQoL as the most important PROM. As for timing of data collection, 37.1% responded most important timing of data collection was prior to adjuvant chemotherapy and 24.1% of participants rated HRQoL evaluation 6 months after surgery. Conclusions: This study successfully collected responses from thoracic surgeons in both Europe and Japan. Although still underused, these findings highlight that surgeons increasingly recognize the value of PROMs, particularly in the context of multimodal treatment.
- 6 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (1)
Patient-Reported Outcomes in Thoracic Surgery: An International Survey of European Society of Thoracic Surgeons (ESTS) and Japanese Association for Chest Surgery (JACS) Members
Objectives: This study aimed to evaluate the progress in the collection and interpretation of patient-reported outcomes (PRO) and health-related quality of life (HRQoL) in thoracic surgery. Methods: We invited all members of the European Society of Thoracic Surgeons (ESTS) and the Japanese Association for Chest Surgery (JACS) via e-mail, providing survey information in both English and Japanese. It consisted of 19 questions addressing the use of HRQoL assessment in clinical practice. Results: In total, we received 234 responses: 84 from ESTS, 128 from JACS, and 22 from other societies. The present survey showed that 58.5% of surgeons have never collected HRQoL data in their practice. The EORTC-QLQ-LC29 was the most frequently used questionnaire, reported by 24.7% of participants. A total of 137 (59.6%) responses identified HRQoL as the most important PROM. As for timing of data collection, 37.1% responded most important timing of data collection was prior to adjuvant chemotherapy and 24.1% of participants rated HRQoL evaluation 6 months after surgery. Conclusions: This study successfully collected responses from thoracic surgeons in both Europe and Japan. Although still underused, these findings highlight that surgeons increasingly recognize the value of PROMs, particularly in the context of multimodal treatment.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).